U.S. markets closed

Karuna Therapeutics, Inc. (KRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
133.56+3.94 (+3.04%)
At close: 4:00PM EDT

Karuna Therapeutics, Inc.

33 Arch Street
Suite 3110
Boston, MA 02110
United States
857 449 2244

Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven M. Paul M.D.CEO, Pres & Chairman871.05k31.02M1951
Dr. Andrew Craig MillerCo-Founder & COO646.55k17.74M1982
Dr. Troy A. IgnelziCFO & Sec.596.55k4.79M1968
Dr. Stephen K. BrannanChief Medical Officer624.55k4.94M1956
Mr. Jason Parker BrownVP of Corp. Fin.N/AN/AN/A
Ms. Mia Kelley J.D.VP of Legal AffairsN/AN/AN/A
Ms. Sharon Sawchak R.N.VP of Clinical Operations & ComplianceN/AN/AN/A
Ms. Stephanie MooreVP of HRN/AN/AN/A
Dr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorN/AN/AN/A
Dr. Ronald N. MarcusSr. VP of MedicalN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Corporate Governance

Karuna Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.